121 related articles for article (PubMed ID: 7708256)
1. Progression of renal failure in the Han: SPRD polycystic kidney rat.
Zeier M; Pohlmeyer G; Deerberg F; Schönherr R; Ritz E
Nephrol Dial Transplant; 1994; 9(12):1734-9. PubMed ID: 7708256
[TBL] [Abstract][Full Text] [Related]
2. Autoregulation of renal blood flow and pressure-dependent renin release in autosomal dominant polycystic kidney disease of rats.
Braun C; Lüdicke C; Rebsch W; Gretz N; van der Woude FJ; Rohmeiss P
Nephrol Dial Transplant; 1996; 11 Suppl 6():52-7. PubMed ID: 9044329
[TBL] [Abstract][Full Text] [Related]
3. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease.
Gattone VH; Siqueira TM; Powell CR; Trambaugh CM; Lingeman JE; Shalhav AL
Exp Biol Med (Maywood); 2008 Aug; 233(8):952-7. PubMed ID: 18480417
[TBL] [Abstract][Full Text] [Related]
4. [Effect of a modified low protein and low fat diet on histologic changes and metabolism in kidneys in an experimental model of polycystic kidney disease].
Banković-Calić N; Ogbori MR; Nicman E
Srp Arh Celok Lek; 2002; 130(7-8):251-7. PubMed ID: 12585002
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
Wahl PR; Serra AL; Le Hir M; Molle KD; Hall MN; Wüthrich RP
Nephrol Dial Transplant; 2006 Mar; 21(3):598-604. PubMed ID: 16221708
[TBL] [Abstract][Full Text] [Related]
6. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model.
Zafar I; Tao Y; Falk S; McFann K; Schrier RW; Edelstein CL
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F854-9. PubMed ID: 17581927
[TBL] [Abstract][Full Text] [Related]
7. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease.
Tao Y; Kim J; Schrier RW; Edelstein CL
J Am Soc Nephrol; 2005 Jan; 16(1):46-51. PubMed ID: 15563559
[TBL] [Abstract][Full Text] [Related]
8. The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats.
Wang D; Braendstrup O; Larsen S; Horn T; Strandgaard S
APMIS; 2004 Jun; 112(6):358-68. PubMed ID: 15511273
[TBL] [Abstract][Full Text] [Related]
9. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
Dai B; Liu Y; Mei C; Fu L; Xiong X; Zhang Y; Shen X; Hua Z
Clin Sci (Lond); 2010 Jul; 119(8):323-33. PubMed ID: 20507283
[TBL] [Abstract][Full Text] [Related]
10. A new in vitro bioassay for cyst formation by renal cells from an autosomal dominant rat model of polycystic kidney disease.
Pey R; Bach J; Schieren G; Gretz N; Hafner M
In Vitro Cell Dev Biol Anim; 1999; 35(10):571-9. PubMed ID: 10614866
[TBL] [Abstract][Full Text] [Related]
11. Hereditary error in epidermal growth factor prohormone metabolism in a rat model of autosomal dominant polycystic kidney disease.
Lakshmanan J; Eysselein V
Biochem Biophys Res Commun; 1993 Dec; 197(3):1083-93. PubMed ID: 8280123
[TBL] [Abstract][Full Text] [Related]
12. Hypertension and renal injury in experimental polycystic kidney disease.
Kennefick TM; Al-Nimri MA; Oyama TT; Thompson MM; Kelly FJ; Chapman JG; Anderson S
Kidney Int; 1999 Dec; 56(6):2181-90. PubMed ID: 10594794
[TBL] [Abstract][Full Text] [Related]
13. [Molecular mechanisms of nephro-protective action of enalapril in experimental chronic renal failure].
Ciechanowicz A
Ann Acad Med Stetin; 1999; Suppl 52():1-93. PubMed ID: 10589103
[TBL] [Abstract][Full Text] [Related]
14. Renal hypertension in rats with hereditary polycystic kidney disease.
Kaspareit-Rittinghausen J; Deerberg F; Rapp KG; Wcislo A
Z Versuchstierkd; 1990; 33(5):201-4. PubMed ID: 2267865
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease.
Schäfer K; Gretz N; Bader M; Oberbäumer I; Eckardt KU; Kriz W; Bachmann S
Kidney Int; 1994 Jul; 46(1):134-52. PubMed ID: 7933831
[TBL] [Abstract][Full Text] [Related]
16. Effect of enalapril on blood pressure, renal function, and the renin-angiotensin-aldosterone system in cats with autosomal dominant polycystic kidney disease.
Miller RH; Lehmkuhl LB; Smeak DD; DiBartola SP; Radin J
Am J Vet Res; 1999 Dec; 60(12):1516-25. PubMed ID: 10622161
[TBL] [Abstract][Full Text] [Related]
17. The Han:SPRD rat is not a genetic model of human autosomal dominant polycystic kidney disease type 1.
Nauta J; Goedbloed MA; Luider TM; Hoogeveen AT; van den Ouweland AM; Halley DJ
Lab Anim; 1997 Jul; 31(3):241-7. PubMed ID: 9230505
[TBL] [Abstract][Full Text] [Related]
18. Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease.
Lawson CR; Doulton TW; MacGregor GA
J Renin Angiotensin Aldosterone Syst; 2006 Sep; 7(3):139-45. PubMed ID: 17094050
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus ameliorates the enhanced expression of metalloproteinases in a rat model of autosomal dominant polycystic kidney disease.
Berthier CC; Wahl PR; Le Hir M; Marti HP; Wagner U; Rehrauer H; Wüthrich RP; Serra AL
Nephrol Dial Transplant; 2008 Mar; 23(3):880-9. PubMed ID: 18042615
[TBL] [Abstract][Full Text] [Related]
20. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats.
Cowley BD; Rupp JC; Muessel MJ; Gattone VH
Am J Kidney Dis; 1997 Feb; 29(2):265-72. PubMed ID: 9016899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
